Glioblastoma Cells Follow Predictable Paths
Brain cancer cells switch states in patterns researchers can now map, opening possible routes for future treatments.
Updated on Nov. 5, 2026 in Cancer
Researchers from EMBL, the German Cancer Research Center (DKFZ) and the Wellcome Sanger Institute report in Nature that glioblastoma cells shift between states along predictable paths. The work, which analysed tumours from 12 patients, also identified regulators that can push cells toward less malignant, less adaptable states. For people living with or caring for someone with this brain cancer, it points toward treatments that target how tumour cells change rather than only where they sit.
Why it matters
Glioblastoma is hard to treat partly because its cells keep switching behaviour, which helps them adapt and survive therapy. Showing that these changes follow a predictable structure gives researchers a clearer map of what to target, and it arrives as the field searches for new ways beyond current treatments.
The study combined a molecular atlas built from tumours of 12 patients with gene regulation analysis of over 1 million patient-derived glioblastoma cells, and confirmed findings in organoids grown from patient tumour cells. Overexpressing MYT1L reduced cellular plasticity and tumour malignancy in patient-derived cells, but these are laboratory and cell-based results rather than patient outcomes.
The players
EMBL (European Molecular Biology Laboratory)
An intergovernmental research organisation based in Heidelberg, Germany, whose computational teams contributed to the glioblastoma molecular analysis.
German Cancer Research Center (DKFZ)
Germany's largest biomedical research institution, which led the gene regulation research on glioblastoma cell states.
Wellcome Sanger Institute
A UK genomics research institute known for large-scale cancer genome studies, where the work was conducted.
The details
Glioblastoma tumour cells can differ greatly from one another and constantly change their behaviour, moving between cell states. In the study, these states followed stereotypical, predictable paths, and different states occupied different spatial niches inside each tumour, a structure found in every tumour examined. The researchers identified a set of regulators that arrest cells in low-plasticity states, and in patient-derived cells, boosting the gene MYT1L reduced both plasticity and malignancy.
Timeline
Results published in the journal Nature in 2026.
Health Landscape
The study builds on the molecular atlas approach pioneered by institutions such as the Wellcome Sanger Institute, moving from describing tumour composition toward mapping how cells change state over time. This shift matters because treatment resistance in cancers like glioblastoma is increasingly understood as a problem of cell plasticity rather than fixed tumour subtypes.
If you or a family member has been diagnosed with glioblastoma, this research is early-stage and will not change current care, so keep discussing treatment options with your oncology team. It is worth asking your doctor whether ongoing clinical trials are exploring therapies that target tumour cell plasticity.
The takeaway
Glioblastoma cells change their behaviour along predictable patterns, which may eventually allow treatments to lock them into less dangerous states. Anyone with questions about brain cancer treatment should raise them with a specialist, who can explain what current options and trials mean for their situation.
Further reading
For broader context on how tumours adapt and resist therapy, explore our Cancer coverage.
